Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.66 |
| ▸ | MEN1 | O00255 | 3/20 | 0.66 |
| ▸ | GFER | P55789 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | PDE5A | O76074 | 4/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
| ▸ | CDC7 | O00311 | 1/20 | 0.40 |
| ▸ | PLK4 | O00444 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13181182 | 0.84 | KMT2A (0.66) | KMT2AMEN1GFERPKMTSHR | |
| SCHEMBL580682 | 0.82 | MEN1 (0.63) | KMT2AMEN1GFERPKMTSHR | |
| SCHEMBL18296853 | 0.81 | SMN1; SMN2 (0.68) | KMT2AMEN1GFERPKMTSHR | |
| SCHEMBL12785941 | 0.80 | KMT2A (0.60) | KMT2AMEN1GFERPKMTSHR | |
| SCHEMBL2210096 | 0.80 | MEN1 (1.00) | KMT2AMEN1GFERPKMTSHR | |
| Hydrochloric Acid SCHEMBL1268228 | 0.79 | KMT2A (0.59) | KMT2AMEN1GFERPKMTSHR | |
| SCHEMBL2125396 | 0.79 | MEN1 (0.55) | KMT2AMEN1GFERPKMTSHR | |
| SCHEMBL27829670 | 0.78 | KMT2A (0.72) | KMT2AMEN1GFERPKMTSHR | |
| SCHEMBL11177213 | 0.77 | MAPT (0.53) | KMT2AMEN1GFERPKMTSHR | |
| SCHEMBL21221819 | 0.77 | MEN1 (0.56) | KMT2AMEN1GFERPKMTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210147359-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-10934256-B2 | Compounds and methods for treating cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-03-02 | — | — | US | disclosed |
| US-10464897-B2 | Compounds and methods for treating cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180148410-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2018-05-31 | — | — | US | disclosed |
| US-20180148410-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2018-05-31 | — | — | US | disclosed |
| WO-2016196879-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-12-08 | — | — | WO | disclosed |
| US-5292738-A | Anti-virally active pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1994-03-08 | — | — | US | disclosed |
| US-5157035-A | Viricides | JANSSEN PHARMACEUTICA N. V. (BE) | 1992-10-20 | — | — | US | disclosed |
| US-5001125-A | Anti-virally active pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-03-19 | — | — | US | disclosed |
| EP-0156433-B1 | ANTI-VIRALLY ACTIVE PYRIDAZINAMINES | JANSSEN PHARMACEUTICA N.V. (BE) | 1991-02-27 | — | — | EP | disclosed |
| EP-0156433-A2 | Anti-virally active pyridazinamines | JANSSEN PHARMACEUTICA N.V. (BE) | 1985-10-02 | — | — | EP | disclosed |
| EP-0009655-B1 | 6-AMINO SUBSTITUTED N-PYRROLYL-3-PYRIDAZINE AMINES, THEIR PREPARATION, AND PHARMACEUTICALLY ANTIHYPERTENSIVE COMPOSITIONS CONTAINING THEM | GRUPPO LEPETIT S.P.A. (IT) | 1983-05-11 | — | — | EP | disclosed |
| US-4247551-A | N-Pyrrolyl-pyridazineamines and their use as antihypertensive agents | GRUPPO LEPETIT S.P.A. (IT) | 1981-01-27 | — | — | US | disclosed |
| EP-0009655-A1 | 6-Amino substituted N-pyrrolyl-3-pyridazine amines, their preparation, and pharmaceutically antihypertensive compositions containing them | GRUPPO LEPETIT S.P.A. (IT) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148410-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | GLI1, SHH, HRAS | KMT2A 1177/4885MEN1 2171/4885GFER 3539/4885 |
| US-20210147359-A1 | COMPOUNDS AND METHODS FOR TREATING CANCER | GLI1, SHH, SMO | KMT2A 1091/4885MEN1 2194/4885GFER 3509/4885 |
| US-10934256-B2 | Compounds and methods for treating cancer | GLI1, SHH, HRAS | KMT2A 1177/4885MEN1 2171/4885GFER 3539/4885 |
| US-10464897-B2 | Compounds and methods for treating cancer | GLI1, SHH, HRAS | KMT2A 1177/4885MEN1 2171/4885GFER 3539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.